These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11365805)

  • 1. Crixivan warning: keep to three times a day.
    Gilden D
    GMHC Treat Issues; 1998 Sep; 12(9):2. PubMed ID: 11365805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twice daily Indinavir trial stopped.
    TreatmentUpdate; 1998 Oct; 10(8):3-4. PubMed ID: 11365875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Merck discontinues twice-daily dosing of Crixivan.
    Res Initiat Treat Action; 1998 Oct; 4(6):13. PubMed ID: 11365914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice-a-day Crixivan study discontinued.
    Newsline People AIDS Coalit N Y; 1998; ():31. PubMed ID: 11367502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twice-daily dosing Crixivan study discontinued.
    WORLD; 1998 Oct; (No 90):7. PubMed ID: 11365922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crixivan (Indinavir): three doses daily, not two, in most regimens.
    James JS
    AIDS Treat News; 1998 Oct; (No 304):4-5. PubMed ID: 11365863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
    Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
    Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
    Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
    Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indinavir, nelfinavir -- twice a day?
    TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ritonavir/indinavir combination study shows promising dosing results.
    AIDS Patient Care STDS; 1998 Feb; 12(2):146-7. PubMed ID: 11361915
    [No Abstract]   [Full Text] [Related]  

  • 11. Twice-daily Indinavir dosing not recommended.
    Highleyman L
    BETA; 1998 Oct; ():4. PubMed ID: 11365990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No more twice-a-day Crixivan.
    Vazquez E
    Posit Aware; 1998; 9(6):17. PubMed ID: 11366469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crixivan, Norvir combination therapy studied.
    Strain W
    Posit Living; 1999 Apr; 8(3):16. PubMed ID: 12492057
    [No Abstract]   [Full Text] [Related]  

  • 14. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin.
    Hamzeh FM; Benson C; Gerber J; Currier J; McCrea J; Deutsch P; Ruan P; Wu H; Lee J; Flexner C;
    Clin Pharmacol Ther; 2003 Mar; 73(3):159-69. PubMed ID: 12621381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
    von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
    Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How to administer indinavir. Consensus group].
    Gatell JM
    Enferm Infecc Microbiol Clin; 1999; 17(7):354-5. PubMed ID: 10535190
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
    Boyd M; Mootsikapun P; Burger D; Chuenyam T; Ubolyam S; Mahanontharit A; Sangkote J; Bunyaprawit P; Horsakulchai M; Lange J; Cooper D; Phanuphak P; Ruxrungtham K
    Antivir Ther; 2005; 10(2):301-7. PubMed ID: 15865224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients.
    Justesen US; Andersen AB; Klitgaard NA; Brøsen K; Gerstoft J; Pedersen C
    Clin Infect Dis; 2004 Feb; 38(3):426-9. PubMed ID: 14727216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR).
    Wasmuth JC; la Porte CJ; Schneider K; Burger DM; Rockstroh JK
    Antivir Ther; 2004 Apr; 9(2):213-20. PubMed ID: 15134183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.